11-May-2023 | D | Outcome of Board Meeting held on May 11, 2023 - Audited Financial Results and recommendation of Final Dividend for financial year 2022-2023
| 11-Jul-2023 | |
10-May-2022 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2022, inter alia, have recommended payment of final dividend of Rs. 5.00/- (50%) per equity share on a face value of Rs.10 each, subject to the approval of members of the Company. | 14-Jul-2022 | |
11-May-2021 | D | Board recommended Final Dividend for FY 20-21 | 29-Jun-2021 | |
03-Nov-2020 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 03, 2020, inter alia, has declared and approved payment of Interim Dividend @ Rs..2.00/- (20%) per equity share of Rs. 10/- each for the Financial Year 2020-21.
The said Interim Dividend shall be paid/dispatched on November 27, 2020. | 10-Nov-2020 | |
11-Feb-2020 | D | Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015'), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. February 11, 2020, has inter alia, declared and approved payment of Interim Dividend @ Rs.2.00/- (20%) per equity share of Rs. 10/- each for the Financial Year 2019-20. The Record Date for payment of Dividend is Feb 20, 2020.
This is for your information and records. | 18-Feb-2020 | |
16-May-2019 | D | Board approved Dividend for FY 2018-19 | 27-Jun-2019 | |
20-May-2016 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 20, 2016, inter alia:
1. Have recommended payment of dividend of 20% at Rs. 2.00/- per equity share on a face value of Rs. 10 each, subject to the approval of members of the Company. | 04-Aug-2016 | |
08-May-2015 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2015, inter alia, have recommended payment of dividend of 15% at Rs.1.50 per equity share on a face value of Rs.10 each, subject to the approval of members of the Company. | 06-Aug-2015 | |
09-May-2014 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 09, 2014, inter alia, have recommended payment of dividend of 30% (including a special dividend of 15%) at Rs. 3 per equity share on a face value of Rs. 10 each, subject to the approval of members of the Company. | 16-Jun-2014 | |
09-May-2014 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 09, 2014, inter alia, have recommended payment of dividend of 30% (including a special dividend of 15%) at Rs. 3 per equity share on a face value of Rs. 10 each, subject to the approval of members of the Company. | 16-Jun-2014 | |
10-May-2013 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2013, inter alia, has:
1. Recommended payment of dividend of Rs. 1.20 per share of a face value of Rs. 10 each, subject to the approval of Bankers and shareholders of the Company. | 24-Jul-2013 | |
01-Jun-2009 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 21, 2009, inter alia, :
1. Have proposed a dividend of 35% on the paid up capital of the company subject to approval of the shareholders in the ensuing Annual General Meeting. | 13-Jul-2009 | |
23-May-2008 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2008, inter alia, has proposed a dividend of 25% on the paid up capital of the Company subject to approval of the shareholders in the ensuing Annual General Meeting. | 17-Jul-2008 | |
18-May-2007 | D | Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2007 has decided to recommend a divided of 25% i.e. Rs 2.50 per share (previous year Rs 2 per share) to the equity share holders for the financial year 2006-07. | 11-Jul-2007 | |
22-Jun-2006 | D | 12% Dividend | 20-Jul-2005 | |
06-Aug-2014 | R | SUB. :- Rights issue of Equity Shares of Neuland Laboratories Ltd. (Scrip Code 524558)
Trading Members of the Exchange are hereby informed that, Neuland Laboratories Ltd. has fixed the Record Date for the purpose of Rights Issue of Equity Shares. The transactions in the equity shares of the Company should be done on ex-rights basis with effect from the under mentioned date.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
Neuland Laboratories Ltd.
(524558)
RECORD DATE
14.08.2014
PURPOSE
Issue of 4 (FOUR) equity shares of Rs. 10/- each for cash at premium of Rs 194/- per share on rights basis for every 25 (TWENTY FIVE) equity shares of Rs. 10/- held.
Ex-Right basis from Date & Sett. No.
13/08/2014 DR-094/2014-2015
NOTE:
Other terms and conditions of the rights issue is attached with this notice.
Trading Members of the Exchange are requested to take note of it. | 14-Aug-2014 | 4:25 |
15-Mar-2012 | R | SUB. :- Rights issue of Equity Shares of Neuland Laboratories Ltd. (Scrip Code 524558)
Trading Members of the Exchange are hereby informed that, Neuland Laboratories Ltd. has fixed the Record Date for the purpose of Rights Issue of Equity Shares. The transactions in the equity
shares of the Company should be done on ex-rights basis with effect from the under mentioned date.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
Neuland Laboratories Ltd.
(524558)
RECORD DATE
23.03.2012
PURPOSE
Issue of 5 (FIVE) Equity Shares of Rs. 10/- each for cash at premium of Rs. 35/- per share on rights basis for every 12 (TWELVE) fully paid up equity shares of Rs. 10/- held.
Ex-Right basis from Date & Sett. No.
21/03/2012 DR-244/2011-2012
Trading Members of the Exchange are requested to take note of it. | 23-Mar-2012 | 5:12 |
23-Apr-2024 | BC | NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Standalone and Consolidat | 10-May-2024 | |
11-May-2023 | BC | 2. Re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737) as Whole Time Director of the Company designated as Executive Chairman, for a further period of 5 (five) years, w.e.f. April 1, 2024, | 01-Apr-2024 | |
31-Mar-2024 | BC | Completion of tenure of an Independent Director | 31-Mar-2024 | |
27-Jun-2023 | BC | Change in Directorate
| 12-Feb-2024 | |
25-Jan-2024 | BC | NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve The Unaudited Financial Results of th | 08-Feb-2024 | |